Concepedia

Author

I. Stasi

Azienda Ospedaliera Universitaria Pisana

Also Known As

I Stasi, I. Stasi, Irene Stasi, Stasi,Irene

59

Publications

1.6K

Citations

9

H-Index

16

Concepts

All Affiliations

Azienda Ospedaliera Universitaria PisanaUniversity of PisaUniversity of UrbinoUniversità Campus Bio-MedicoOspedale di Livorno
IS

About

I. Stasi is an author at Azienda Ospedaliera Universitaria Pisana specializing in oncology, pathology, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

128

2

Pathology

3

3

128

3

Cell Biology

1

1

27

4

Immunology

1

1

27

5

Pharmacology

1

1

70

I. Stasi

×

9

Publications

1.5K

Citations

9

H-Index

YearCitations

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

Fotios Loupakis, Annamaria Ruzzo, Chiara Cremolini,

British Journal of Cancer

2009

557

PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer

Fotios Loupakis, Luca Emanuele Pollina, I. Stasi,

Journal of Clinical Oncology

2009

402

High Concordance of <i>KRAS</i> Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice

Daniele Santini, Fotios Loupakis, Bruno Vincenzi,

The Oncologist

2008

228

Randomized Trial of Two Induction Chemotherapy Regimens in Metastatic Colorectal Cancer: An Updated Analysis

Gianluca Masi, E. Vasile, Fotios Loupakis,

JNCI Journal of the National Cancer Institute

2010

188

Amphiregulin (AR) expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients

Fotios Loupakis, Chiara Cremolini, Gabriele Perrone,

Journal of Clinical Oncology

2009

70

Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: Clinical outcome according to KRAS and BRAF mutational status

Lorenzo Fornaro, Giacomo Giulio Baldi, Gianluca Masi,

Critical Reviews in Oncology/Hematology

2010

31

Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer

I. Stasi, Federico Cappuzzo

Translational Respiratory Medicine

2014

28

Evaluation of PTEN expression in colorectal cancer (CRC) metastases (mets) and in primary tumors as predictors of activity of cetuximab plus irinotecan treatment

Fotios Loupakis, Le Pollina, I. Stasi,

Journal of Clinical Oncology

2008

27

REGOMA-OSS: a large, Italian, multicenter, prospective, observational study evaluating the efficacy and safety of regorafenib in patients with recurrent glioblastoma

Mario Caccese, Isacco Desideri, Veronica Villani,

ESMO Open

2024

15

Page 1